分子影像在肿瘤诊治中的作用已不仅仅是肿瘤的早期显像诊断，在肿瘤的分期、预后评价、疗效监测以及指导个体化治疗等方面都发挥着不可替代的作用。然而，随着医学的发展，单一模态和单一参数的分子影像技术已经无法满足人们对疾病的认识，临床诊断需要更灵敏、更准确、功能更全面的分子影像手段，因此多模态、多参数分子影像已成为医学影像学发展的趋势。多模态多参数分子影像不仅体现在显像仪器本身提供的各种参数，也体现在不同分子探针给出的各种影像学信息。本课题根据乳腺癌发生、发展过程中的不同特点，针对HER2、integrin α6以及肿瘤微环境构建全新分子探针99mTc-HYNIC-HXF、99mTc-HYNIC-CRWY9和99mTc-HYNIC-Var7，以核医学显像为主，通过多模态显像，获得多参数的有关乳腺癌的影像学信息，为乳腺癌的早期显像诊断、肿瘤转移及耐药机制的研究、疗效监测及指导个体化治疗提供方法和手段。

Molecular imaging plays important roles in not only tumor early detection, but also tumor staging, prognosis evaluation, therapeutic monitoring and guiding individual treatment. However, with the development of medical sciences, single modality or single parameter molecular imaging is unable to meet the threshold for the better understanding of diseases. More sensitive, accurate, and comprehensive molecular imaging strategies are urgently needed. Therefore, multimodality and multiparameter molecular imaging has become the trend of modern medical imaging. Multimodality and multiparameter molecular imaging not only refers to the various parameters provided by imaging instruments, but also refers to the different imaging information provided by molecular probes. According to the different characteristics during the progression of breast cancer, this project focuses on the development of new molecular probes including 99mTc-HYNIC-HXF, 99mTc-HYNIC-CRWY9, and 99mTc-HYNIC-Var7 targeting HER2, integrin α6, and tumor microenvironment. Relying on multimodality molecular imaging, especially nuclear medicine imaging, this study would provide multiparameter imaging information for the early detection of breast cancer, investigations of metastasis and resistance to therapy, monitoring therapy, and guiding personalized therapy.